RecruitingNCT07473804

Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

25 participants

Start Date

Apr 14, 2025

Study Type

OBSERVATIONAL

Conditions

Congenital Adrenal Hyperplasia (CAH)Neonatal Salt Loss

Summary

Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neonatal screening. This study examines how often these conditions occur and describes their main clinical, genetic, and treatment features.

Eligibility

Min Age: 1 YearMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with congenital adrenal hyperplasia (cah) and neonatal salt loss. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 35 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07473804

Related Trials

Natural History Study of Patients With Excess Androgen

NCT002501592 locations

Fertility And Sexual Function In CAH: CALLIOPE

NCT070994561 location